+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Spinal Muscular Atrophy Treatment Market - Global Forecast 2026-2032- Product Image
Spinal Muscular Atrophy Treatment Market - Global Forecast 2026-2032- Product Image
Sale

Spinal Muscular Atrophy Treatment Market - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6012079
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Spinal Muscular Atrophy Treatment Market is projected to reach USD 5.36 Billion in 2026. It is expected to continue growing at a CAGR of 10.97%, reaching USD 10.08 Billion by 2032.

Spinal muscular atrophy treatment has shifted from supportive management to disease-modifying intervention, creating one of the most important precision-medicine areas in rare neuromuscular care. SMA is most commonly caused by biallelic loss or mutation of the SMN1 gene, with disease severity influenced by SMN2 copy number. Epidemiologic literature commonly reports SMA incidence at roughly 1 in 6,000 to 1 in 10,000 live births, making early diagnosis and timely therapy central to clinical outcomes.

The treatment landscape is anchored by three approved disease-modifying options: nusinersen, an intrathecal antisense oligonucleotide first approved by the U.S. FDA in 2016; onasemnogene abeparvovec, an AAV9-based gene replacement therapy first approved in 2019; and risdiplam, an oral SMN2 splicing modifier first approved in 2020. These therapies have redefined survival, motor milestone achievement, and long-term care planning, while also elevating the importance of newborn screening, genetic counseling, payer evidence, and post-marketing safety monitoring.

Transformative Shifts in the SMA Treatment Landscape

The most significant shift in the SMA treatment landscape is the move toward presymptomatic treatment. Clinical and real-world evidence consistently shows that patients treated before irreversible motor neuron loss generally achieve better functional outcomes than those treated after symptom onset. This has made newborn screening a strategic enabler, particularly in countries and health systems that have added SMA to national or regional screening panels.

Another transformative shift is the transition from single-product decision-making to lifecycle treatment strategy. Clinicians, payers, and families are increasingly evaluating route of administration, durability of response, safety profile, age and weight eligibility, intrathecal access, oral adherence, and the evidence base for switching or sequencing therapies. Manufacturers must therefore compete not only on efficacy, but also on long-term outcomes, access support, registry evidence, and value demonstration.

Cumulative Impact of Artificial Intelligence on SMA Treatment

Artificial intelligence is becoming a practical accelerator across SMA diagnosis, treatment monitoring, and market access. In clinical care, AI-enabled analytics can support earlier identification of delayed motor milestones, prioritize genetic testing workflows, and analyze digital biomarkers from wearables or video-based motor assessments. These applications are especially relevant because treatment timing is a major determinant of outcome in SMA.

For health systems, AI is improving real-world evidence generation by structuring registry data, identifying treatment-response patterns, and supporting pharmacovigilance signal detection. In market access, predictive modeling can help assess patient identification pathways, care burden, and long-term outcomes, provided models remain transparent, clinically validated, and compliant with privacy and health-data governance requirements.

Key Regional Insights Across Global SMA Treatment Markets

North America remains a leading region for SMA treatment adoption due to established newborn screening, high specialist density, mature payer infrastructure, and early availability of FDA-approved therapies. The United States has been especially influential because SMA was added to the Recommended Uniform Screening Panel in 2018, supporting broader presymptomatic diagnosis. Canada continues to expand access through provincial reimbursement decisions and specialist-led neuromuscular networks.

Europe is characterized by strong regulatory oversight through the European Medicines Agency and country-specific reimbursement pathways that assess clinical value, budget impact, and long-term evidence. The European Union benefits from cross-border rare disease collaboration, while the United Kingdom, Germany, France, Italy, and Spain remain important treatment and evidence-generation markets. Asia-Pacific is expanding as Japan, Australia, South Korea, China, and India increase genetic testing capacity, rare disease policy attention, and access to disease-modifying therapies.

Latin America, the Middle East, and Africa present important but uneven-access environments. Brazil and Mexico anchor Latin American demand, while Middle Eastern countries, particularly in the GCC, are investing in genomic medicine, newborn screening, and advanced therapies. In Africa, access is constrained by diagnostic infrastructure, affordability, and specialist availability, but newborn screening pilots, philanthropic programs, and regional rare disease advocacy are creating a foundation for future treatment access.

Key Group Insights for SMA Treatment Adoption

The G7 markets remain central to SMA treatment commercialization because they combine high healthcare expenditure, advanced regulatory systems, and established rare disease reimbursement frameworks. The United States, Canada, Japan, Germany, France, Italy, and the United Kingdom shape clinical evidence expectations, registry design, and payer standards for high-cost therapies, including gene therapy and chronic SMN2-targeted treatment.

The European Union provides a coordinated regulatory environment and growing rare disease data infrastructure, but reimbursement remains country-specific and frequently tied to health technology assessment outcomes. BRICS countries offer major long-term treatment-access potential because of large birth cohorts and expanding genetic medicine capabilities, although affordability, reimbursement variability, and unequal diagnostic coverage remain critical barriers.

ASEAN markets are progressing through specialist-center development and selective access programs, with adoption depending heavily on public funding and diagnostic reach. GCC countries are prioritizing genomics, newborn screening, and tertiary care investment, creating a favorable environment for advanced SMA therapies. NATO is not a healthcare market, but its member economies include many strong rare disease systems, supporting supply-chain resilience, regulatory alignment, and clinical research collaboration.

Key Country Insights Shaping SMA Treatment Demand

The United States is the most influential SMA treatment market due to early approvals, broad newborn screening adoption, and a large ecosystem of neuromuscular centers, patient advocacy organizations, and specialty pharmacies. Canada has a smaller but highly structured environment shaped by provincial reimbursement and specialist consensus. Mexico and Brazil represent important Latin American access opportunities, with treatment availability dependent on public-sector funding, private insurance coverage, and legal or policy mechanisms for high-cost rare disease therapies.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have established pathways for SMA therapy access, although reimbursement criteria can differ by age, SMA type, functional status, and evidence requirements. Russia has domestic rare disease policy mechanisms but faces procurement and access variability. China is scaling rare disease policy, genetic testing, and inclusion mechanisms, while India combines substantial unmet need with affordability challenges and growing genetic diagnostics capacity.

Japan, Australia, and South Korea are mature Asia-Pacific markets with advanced regulatory systems and specialist neuromuscular care. Japan has been an early adopter of innovative rare disease therapies, Australia benefits from newborn screening expansion and public reimbursement review processes, and South Korea continues to strengthen access through national insurance assessment and tertiary-care concentration.

Actionable Recommendations for SMA Industry Leaders

Industry leaders should prioritize earlier diagnosis by supporting newborn screening expansion, confirmatory genetic testing capacity, and clinician education across pediatrics, neurology, and genetics. Because SMA outcomes are highly time-sensitive, sustainable adoption depends on shortening the pathway from birth to diagnosis to treatment initiation.

Organizations should invest in long-term real-world evidence, including motor function, respiratory outcomes, survival, caregiver burden, treatment persistence, safety, and health-economic endpoints. Access strategies should be tailored to each market’s reimbursement model, with outcomes-based agreements, registries, and patient support programs used where appropriate. Leaders should also build resilient manufacturing and cold-chain capabilities for advanced therapies while maintaining transparent communication around safety monitoring and treatment durability.

Research Methodology for SMA Treatment Analysis

This executive summary is based on secondary research of verified public sources, including regulatory agency approvals, peer-reviewed epidemiology and clinical literature, newborn screening policy references, health technology assessment trends, and publicly available rare disease access information. The analysis emphasizes data-backed developments rather than speculative claims.

The methodology combines disease epidemiology, treatment approval history, regional access assessment, policy review, and qualitative market interpretation. Key analytical variables include approved therapy availability, newborn screening maturity, reimbursement readiness, specialist infrastructure, genetic testing capacity, real-world evidence generation, and health-system affordability.

Conclusion: The Future of SMA Treatment

The SMA treatment landscape is entering a more complex phase defined by earlier diagnosis, multiple therapeutic modalities, payer scrutiny, and demand for durable real-world evidence. Disease-modifying therapies have changed the clinical trajectory of SMA, but access remains uneven across regions and income levels.

Future competitive advantage will depend on evidence depth, speed of diagnosis, treatment personalization, and sustainable reimbursement. Organizations that align clinical innovation with newborn screening, data infrastructure, patient support, and regional access strategies will be best positioned to advance global spinal muscular atrophy treatment access.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Spinal Muscular Atrophy Treatment Market, by Disease Type
7.1. Introduction
7.2. Type 1 SMA
7.3. Type 2 SMA
7.4. Type 3 SMA
7.5. Type 4 SMA
8. Spinal Muscular Atrophy Treatment Market, by Treatment Type
8.1. Introduction
8.2. Gene Therapy
8.3. Drug Therapy
8.3.1. Nusinersen
8.3.2. Risdiplam
9. Spinal Muscular Atrophy Treatment Market, by Route of Administration
9.1. Introduction
9.2. Oral
9.3. Intrathecal
9.4. Intravenous
10. Spinal Muscular Atrophy Treatment Market, by End User
10.1. Introduction
10.2. Homecare Settings
10.3. Hospitals
10.4. Specialty Clinics
10.5. Neurology Centers
10.6. Research Institutes
11. Spinal Muscular Atrophy Treatment Market, by Distribution Channel
11.1. Introduction
11.2. Online Pharmacies
11.3. Offline Pharmacies
12. Spinal Muscular Atrophy Treatment Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Spinal Muscular Atrophy Treatment Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Spinal Muscular Atrophy Treatment Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Astellas Pharma Inc
16.2. Biogen Inc
16.3. Biohaven Ltd
16.4. Chugai Pharmaceutical Co Ltd
16.5. Cytokinetics Inc
16.6. F. Hoffmann-La Roche AG
16.7. Ionis Pharmaceuticals Inc
16.8. Natco Pharma
16.9. NMD Pharma A/S
16.10. Novartis AG
16.11. Pfizer Inc
16.12. PTC Therapeutics Inc
16.13. REGENXBIO Inc
16.14. Sarepta Therapeutics Inc
16.15. Scholar Rock Inc
16.16. Shionogi & Co Ltd
16.17. Vertex Pharmaceuticals Inc
List of Figures
FIGURE 1. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL TYPE 1 SMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL TYPE 1 SMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL TYPE 1 SMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL TYPE 2 SMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL TYPE 2 SMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL TYPE 2 SMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL TYPE 3 SMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL TYPE 3 SMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL TYPE 3 SMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL TYPE 4 SMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL TYPE 4 SMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL TYPE 4 SMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL DRUG THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL DRUG THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL DRUG THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL NUSINERSEN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL NUSINERSEN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL NUSINERSEN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL RISDIPLAM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL RISDIPLAM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL RISDIPLAM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL INTRATHECAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL INTRATHECAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL INTRATHECAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL NEUROLOGY CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL NEUROLOGY CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL NEUROLOGY CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL OFFLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL OFFLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL OFFLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 65. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 66. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 67. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 68. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 69. ASIA-PACIFIC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 70. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 72. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 73. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 74. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 75. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 76. NORTH AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 77. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 79. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 80. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 81. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 82. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 83. LATIN AMERICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 84. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 86. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 87. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 88. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 89. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 90. EUROPE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 91. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 93. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 94. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 95. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 96. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 97. MIDDLE EAST SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 98. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 100. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 101. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 102. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 103. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 104. AFRICA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 108. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 109. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 110. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 111. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 112. ASEAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 113. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 115. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 116. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 117. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 118. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 119. GCC SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 120. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 122. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 123. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 124. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 125. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 126. EUROPEAN UNION SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 127. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 129. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 130. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 131. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 132. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 133. BRICS SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 134. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 136. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 137. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 138. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 139. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 140. G7 SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 141. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 143. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 144. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 145. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 146. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 147. NATO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 149. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 150. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 151. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 152. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 153. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 154. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 155. UNITED STATES SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 156. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 157. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 158. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 159. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 160. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 161. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 162. CANADA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 163. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 164. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 165. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 166. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 167. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 168. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 169. MEXICO SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 170. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 171. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 172. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 173. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 174. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 175. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. BRAZIL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 177. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 178. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 179. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 180. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 181. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 182. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 183. UNITED KINGDOM SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 184. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 185. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 186. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 187. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 188. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 189. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 190. GERMANY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 191. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 192. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 193. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 194. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 195. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 196. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 197. FRANCE SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 198. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 199. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 200. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 201. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 202. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 203. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 204. RUSSIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 205. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 206. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 207. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 208. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 209. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 210. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 211. ITALY SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 212. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 213. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 214. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 215. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 216. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 217. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 218. SPAIN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 219. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 220. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 221. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 222. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 223. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 224. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 225. CHINA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 226. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 227. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 228. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 229. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 230. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 231. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 232. INDIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 233. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 234. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 235. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 236. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 237. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 238. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 239. JAPAN SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 240. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 241. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 242. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 243. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 244. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 245. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 246. AUSTRALIA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 247. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 248. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 249. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2017-2032 (USD MILLION)
TABLE 250. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DRUG THERAPY, 2017-2032 (USD MILLION)
TABLE 251. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 252. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 253. SOUTH KOREA SPINAL MUSCULAR ATROPHY TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 254. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
TABLE 255. GLOBAL SPINAL MUSCULAR ATROPHY TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Astellas Pharma Inc
  • Biogen Inc
  • Biohaven Ltd
  • Chugai Pharmaceutical Co Ltd
  • Cytokinetics Inc
  • F. Hoffmann-La Roche AG
  • Ionis Pharmaceuticals Inc
  • Natco Pharma
  • NMD Pharma A/S
  • Novartis AG
  • Pfizer Inc
  • PTC Therapeutics Inc
  • REGENXBIO Inc
  • Sarepta Therapeutics Inc
  • Scholar Rock Inc
  • Shionogi & Co Ltd
  • Vertex Pharmaceuticals Inc

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 5.36 Billion
Forecasted Market Value ( USD ) by 2032 $ 10.08 Billion
Compound Annual Growth Rate10.9%
Regions CoveredGlobal
No. of Companies Mentioned17

Related Topics

Related Reports

Drugs for Spinal Muscular Atrophy Market - Global Forecast 2026-2032 - Product Image

Drugs for Spinal Muscular Atrophy Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Spinal Muscular Atrophy - Global Strategic Business Report - Product Image

Spinal Muscular Atrophy - Global Strategic Business Report

  • Report
  • 160 Pages
  • Global
From
Spinal Muscular Atrophy (SMA) Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Spinal Muscular Atrophy (SMA) Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 73 Pages
  • Global
From
Spinal Muscular Atrophy Treatment Market Report 2026 - Product Image

Spinal Muscular Atrophy Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Spinal Muscular Atrophy Market Report 2026 - Product Image

Spinal Muscular Atrophy Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.